Focused On-demand Library for AP-3 complex subunit delta-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O14617

UPID:

AP3D1_HUMAN

Alternative names:

AP-3 complex subunit delta; Adaptor-related protein complex 3 subunit delta-1; Delta-adaptin

Alternative UPACC:

O14617; O00202; O75262; Q59HF5; Q96G11; Q9H3C6

Background:

The AP-3 complex subunit delta-1, also known as Adaptor-related protein complex 3 subunit delta-1 or Delta-adaptin, plays a crucial role in the trafficking of vesicles from the Golgi membrane, potentially directing them towards lysosomes. It is integral to the process of CD8+ T-cell and NK cell degranulation and works alongside the BLOC-1 complex to ensure proper cargo delivery into neurites and nerve terminals.

Therapeutic significance:

Given its involvement in Hermansky-Pudlak syndrome 10, a disorder characterized by albinism, neutropenia, and immunodeficiency, understanding the role of AP-3 complex subunit delta-1 could open doors to potential therapeutic strategies. Its function in vesicle trafficking and immune cell degranulation highlights its potential as a target for therapeutic intervention in related diseases.